Celastrol Potentiates Radiotherapy by Impairment of DNA Damage Processing in Human Prostate Cancer

Celastrol sensitized PC-3 cells to radiation both in vitro and in vivo by impairing DNA damage processing and augmenting apoptosis. Celastrol might represent a promising new adjuvant regimen for the treatment of hormone-refractory prostate cancer.